Quality Assessment of Diagnostic Studies on Using Anti-cyclic Citrullonated Peptide Antibody to Diagnose Rheumatoid Arthritis_Chinese Journal of Evidence-Based Medicine

Authors：

YI Kang ¹³ , WANG Yunfang ¹³ , TIAN Jinhui ¹² , MA Bin ¹² , ZHAO Fenghui ¹⁴ ,  YANG Kehu ¹²

1. Evidence-based Medicine Center of Lanzhou University, Lanzhou 730000, China;2. School of Basic Medical Science of Lanzhou University, Lanzhou 730000, China;3. The First Clinical College of Lanzhou University, Lanzhou 730000, China;4. School of Public Health of Lanzhou University, Lanzhou 730000, China;

Corresponding author：

YANG Kehu, Email: yangkh2006@163.com

Keywords：

Anti-cyclic citrullonated peptide antibody; Rheumatoid arthritis; Diagnostic test; Quality assessment

DOI：

10.7507/1672-2531.20090020

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective 　To evaluate the quality of diagnostic studies on detecting anti-cyclic citrullonated peptide antibody to diagnose rheumatoid arthritis.
Methods 　We searched PubMed, EMbase, The Cochrane Library, and CBM to collect studies on using anti-cyclic citrullonated peptide antibody to diagnose rheumatoid arthritis. QUADAS items were used to evaluate the quality of included studies.
Results 　A total of 195 studies were included. Sixty-nine were English studies and 126 were Chinese studies. All studies had good descriptions of the spectrum of patients and little potential for partial verification bias, differential verification bias, and incorporation bias. However, most studies were prone to disease progression bias, review bias, and clinical review bias. One study did not explain the intermediate test results, and another did not report part of the test results. The overall quality of English studies was better than that of Chinese studies.
Conclusion 　 The potential bias of the included studies mainly resulted from the absence of blinding when interpreting the test results. The reporting quality of the included studies was poor.

Citation： YI Kang,WANG Yunfang,TIAN Jinhui,MA Bin,ZHAO Fenghui,YANG Kehu. Quality Assessment of Diagnostic Studies on Using Anti-cyclic Citrullonated Peptide Antibody to Diagnose Rheumatoid Arthritis. Chinese Journal of Evidence-Based Medicine, 2009, 09(1): 99-106. doi: 10.7507/1672-2531.20090020 Copy

1.	Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum, 1988, 31: 315-324.
2.	Masura J, Walsh KP, Thanopoulous B, et al. Catheter closure of moderate to large-sized patient ductus arteriosus using the new Amplatzer Duct Occluder:Immediate and short-term results. J Am Coll Cardiol, 1998, 31: 878-882.
3.	Sehellekens GA, Visser H, De Jong BA, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullonated peptide. Arthritis Rheum, 2000, 43: 155-163.
4.	Whiting PF, Weswood ME, Rutjes AW, et al. Evaluation of QUADAS, a tool for the quality assessment of diagnostic accuracy studies. BMC Med Res Methodol, 2006, 6: 9.
5.	Patrick M, Bossuyt JB, Reitsma DE, et al. The STARD statement for reporting studies of diagnosis accuracy: explanation and elaboration. Croat Med J, 2003, 44: 639-650.
6.	陈华丽, 杨文东, 韩景银. 抗CCP抗体与RF联合检测诊断类风湿关节炎的价值. 齐鲁医学杂志, 2007, 22(6): 508-510.
7.	陈红梅, 孙明忠. 抗环瓜氨酸肽抗体与RF联合检测在RA诊断中的应用. 现代检验医学杂志, 2007, 22(4): 79-80.
8.	陈俊伟, 李小峰. 抗环瓜氨酸肽抗体在风湿性疾病中的意义. 基层医学论坛, 2007, 11(8): 668-669.
9.	符克英, 陈汝, 占锋, 等. 类风湿因子、AKA和抗CCP抗体检测在类风湿关节炎的诊断价值. 中国热带医学, 2007, 7(11): 2029-2030.
10.	顾福荣, 张义东. 抗CCP抗体、抗RA33抗体、抗Sa抗体和RF联合检测对类风湿性关节炎诊断的意义. 江西医学检验, 2007, 25(1): 24-25.
11.	胡学亭, 夏祥阶, 魏红, 等. 血清抗环瓜氨酸肽抗体和类风湿因子联合检测对类风湿性关节炎的诊断价值. 潍坊医学院学报, 2007, 29(1): 57-58.
12.	胡志东, 吕军强. 抗环瓜氨酸肽抗体和血管内皮生长因子对类风湿关节炎实验诊断意义探讨. 检验医学, 2007, 22(1): 41-43.
13.	乐爱平, 鞠北华, 黄清水, 等.Ⅰ型胶原吡啶交联终肽及抗环瓜氨酸肽抗体等联合检测在类风湿关节炎诊断与病情监测中的应用. 中国实用内科杂志, 2007, 27(23): 1852-1855.
14.	李芳, 许立飞. 抗环瓜氨酸肽抗体在类风湿关节炎中的诊断和鉴别诊断价值. 中国医师进修杂志内科版, 2007, 30(9): 37.
15.	李光迪, 刘芳. 抗环瓜氨酸肽抗体与类风湿因子IgM联合检测在类风湿关节炎早期诊断中的应用. 国际检验医学杂志, 2007, 28(8): 696-698.
16.	刘喜德, 蔡龙, 李召东, 等. 抗环瓜氨酸肽抗体在类风湿关节炎诊断中的意义. 浙江中西医结合杂志, 2007, 17(1): 8-10.
17.	卢芝君, 俞松山. 抗环瓜氨酸肽抗体检测在类风湿性关节炎早期诊断中的临床意义. 全科医学临床与教育, 2007, 5(3): 242-243.
18.	穆春晓. 类风湿关节炎诊断中RF、AKA及抗CCP抗体联检的临床价值. 医学理论与实践, 2007, 20(5): 517-518.
19.	秦白茹, 王亚强. 血清抗环瓜氨酸肽抗体检测在类风湿关节炎中的诊断价值. 现代预防医学, 2007, 34(2): 346.
20.	石宏宴. 抗CCP抗体与RF联合检测在类风湿关节炎中的临床意义. 中国实用医药, 2007, 2(2): 116-117.
21.	宋继军, 潘秀军, 岳晓红. 抗环瓜氨酸肽抗体对类风湿性关节炎诊断的应用价值. 职业与健康, 2007, 23(22): 2020-2021.
22.	宋欣丽, 王颖. 抗环瓜氨酸肽抗体检测在类风湿关节炎中的诊断意义. 陕西医学杂志, 2007, 36(7): 882-883.
23.	苏锡康. 抗环瓜氨酸肽抗体、抗角质蛋白抗体和类风湿因子在类风湿性关节炎诊断中的意义. 江西医学检验, 2007, 25(2): 129-130.
24.	汤卫菊. 抗环状瓜氨酸肽(CCP)抗体检测的临床应用. 中国医药导报, 2007, 4(11).
25.	王丹彤, 陈亮. 抗环瓜氨酸肽抗体、抗角蛋白抗体在类风湿关节炎中的临床意义. 内蒙古医学杂志, 2007, 39(7): 797-798.
26.	王海, 李瑞清, 何建发, 等. 抗环瓜氨酸多肽抗体和类风湿因子联合检测在早期类风湿关节炎诊断中的意义. 实用医学杂志, 2007, 23(13): 2003-2004.
27.	王军, 文爱清. 抗环瓜氨酸肽抗体对类风湿关节炎诊断的临床评价. 重庆医学, 2007, 36(15): 1513-1515.
28.	王嫱, 左晓霞, 游运辉, 等. 抗环瓜氨酸肽抗体在类风湿性关节炎中的检测及临床研究. 中国现代医学杂志, 2007, 17(13): 1645-1648.
29.	王世强. 类风湿性关节炎患者血清抗环瓜氨酸肽抗体的检测分析. 中华临床医学研究杂志, 2007, 13(16): 2420-2421.
30.	王永福, 康丽荣. 联合检测抗环瓜氨酸肽抗体及抗角蛋白抗体在类风湿关节炎患者中的临床意义. 内蒙古医学杂志, 2007, 39(2): 131-132.
31.	韦薇, 钱雅琴. 抗体联合检测在类风湿关节炎早期诊断中的临床意义. 贵州医药, 2007, 31(5): 401-403.
32.	巫翠萍, 覃西. RF、抗-CCP和AKA联合检测在类风湿性关节炎诊断中的价值. 中国热带医学, 2007, 7(8): 1367-1368.
33.	许超尘, 饶华春, 游玉权, 等. 联合检测AKA、抗CCP抗体与RF在类风湿性关节炎诊断中的应用. 中国现代医药杂志, 2007, 9(11): 43-45.
34.	徐惠萍, 齐文成. 抗环瓜氨酸肽抗体在类风湿性关节炎诊断中的研究. 国际医药卫生导报, 2007, 13(4): 14-17.
35.	严利文, 李晶. 抗环瓜氨酸肽抗体在类风湿关节炎中的诊断意义. 江苏大学学报: 医学版, 2007, 17(2): 164-166.
36.	杨春莉, 裘宇容. 对比检测血清中抗环瓜氨酸肽抗体水平对类风湿关节炎的诊断价值. 南方医科大学学报, 2007, 27(8): 1277-1278.
37.	杨平, 杭永论. 抗CCP抗体与RF联合检测在类风湿关节炎早期诊断中的价值. 山东医药, 2007, 47(5).
38.	姚小平. 抗环瓜氨酸肽抗体在类风湿性关节炎诊断和治疗中的应用. 临床和实验医学杂志, 2007, 6(3): 21-22.
39.	蔡文虹, 孙保东, 洪小平, 等. RF、CCP和AKA联合检测在类风湿关节炎诊断中的评价. 临床和实验医学杂志, 2006, 5(6): 671-672.
40.	曹德华, 于虹. 类风湿性关节炎108例血清抗环瓜氨酸肽抗体的检测. 中国误诊学杂志, 2006, 6(8): 1454-1455.
41.	陈敏静, 李珩. 联合检测三种自身免疫抗体在早期类风湿关节炎诊断中的意义. 现代医院, 2006, 6(3): 60-61.
42.	陈晓玲, 潘莎琳. CCP抗体和RF在类风湿性关节炎诊断中的应用. 四川医学, 2006, 27(7): 690-691.
43.	崔华东, 张宁. 抗环瓜氨酸多肽抗体检测早期诊断类风湿关节炎研究. 中国实用内科杂志, 2006, 26(24): 1977-1978.
44.	崔奕文, 鲁荣兵. 类风湿关节炎患者抗-CCP抗体检测的临床意义. 国际检验医学杂志, 2006, 27(10): 949.
45.	顾猛, 丁小兰. 应用ROC曲线分析评价抗环瓜氨酸肽抗体对类风湿性关节炎的诊断价值. 中国现代实用医学杂志, 2006, 5(7): 11-14.
46.	韩玉祥, 邵福灵, 靳洪涛, 等. 抗环瓜氨酸肽抗体在类风湿关节炎诊断中的应用. 中国误诊学杂志, 2006, 6(5): 810-812.
47.	胡清, 王芳, 孙明锦, 等. 抗CCP抗体和抗RA33抗体对老年类风湿关节炎诊断的意义. 中国老年学杂志, 2006, 26(2): 182-183.
48.	赖战峰, 吴晓宁. 抗环瓜氨酸肽抗体定量检测在类风湿关节炎中的诊断价值. 广西医科大学学报, 2006, 23(6): 985-986.
49.	李桂凤, 高峰. 血清中第二代抗环瓜氨酸肽抗体水平的检测在类风湿关节炎中的诊断价值. 中国实验诊断学, 2006, 10(1): 84-87.
50.	李世荣, 马金栋, 王云增, 等. 类风湿性关节炎患者检测抗CCP抗体、抗RA33抗体、CRP的临床价值. 临床检验杂志, 2006, 24(4): 270, 273.
51.	李小龙, 陶洪群. 抗环瓜氨酸肽抗体在类风湿性关节炎诊断中的应用. 检验医学, 2006, 21(6): 599-601.
52.	梁建群, 罗燕飞. 早期类风湿关节炎指标的评价. 实用医学杂志, 2006, 22(15): 1820-1821.
53.	林玲, 肖征宇, 陈肃标, 等. 抗环瓜氨酸肽抗体在类风湿关节炎中的意义. 中国卫生检验杂志, 2006, 16(5): 516-518.
54.	刘黎. 关节液中抗环瓜氨酸肽抗体在类风湿关节炎诊断和评估中的意义. 诊断学理论与实践, 2006, 5(4): 301-303.
55.	孟庆松, 刘小信, 杨宜娥, 等. AKA、APF、RF和抗CCP抗体在类风湿关节炎诊断和鉴别诊断中的应用. 医学检验与临床 2006, 17(6): 35-37.
56.	潘解萍, 谢雯. 抗环瓜氨酸肽抗体在类风湿关节炎早期诊断中的临床意义. 江苏医药, 2006, 32(1): 68-69.
57.	彭晓东, 李立新. 抗CCP抗体、AKA及RF对类风湿性关节炎的诊断价值. 四川大学学报(医学版), 2006, 37(2): 317-318.
58.	任天丽, 石国勋. 血清抗环瓜氨酸肽抗体在类风湿关节炎诊断中的评价. 诊断学理论与实践, 2006, 5(4): 304-305.
59.	谭立明, 彭卫华. 抗环瓜氨酸肽抗体检测在类风湿性关节炎的临床应用研究. 江西医学检验, 2006, 24(4): 312-314.
60.	唐吉斌, 孙芸. 抗CCP抗体与RF联合检测在类风湿关节炎早期诊断中的意义. 检验医学与临床, 2006, 3(1): 12-14.
61.	王剑英, 李萍, 王伟刚. 抗环瓜氨酸肽抗体等四种抗体在早期类风湿关节炎诊断中的意义. 中国实验诊断学, 2006, 10(12): 1446-1448.
62.	王友莲, 胡坚方. 抗环瓜氨酸肽抗体检测对类风湿关节炎的诊断意义. 实用临床医学(江西), 2006, 7(6).
63.	肖长虹, 吴启富. 类风湿关节炎关节液抗环瓜氨酸肽抗体的检测及意义. 中华风湿病学杂志, 2006, 10(3): 184-186.
64.	肖镇, 王勇, 秦毅强, 等. 抗环瓜氨酸肽抗体等三种抗体在类风湿关节炎中的诊断价值. 临床荟萃, 2006, 21(19): 1406-1408.
65.	肖镇, 白丽杰, 秦毅强. 联合检测AFA与抗CCP抗体RF对评估类风湿关节炎的临床意义. 内蒙古医学杂志, 2006, 38(1): 9-12.
66.	余伟, 朱梅英. 抗环瓜氨酸肽抗体、类风湿因子与抗角蛋白抗体在类风湿关节炎诊断中的价值比较. 检验医学, 2006, 21(2): 103-105.
67.	曾瑜, 陈明. 抗环瓜氨酸肽抗体和类风湿因子联合测定对类风湿关节炎的诊断价值. 中国临床医学, 2006, 13(6): 1022-1023.
68.	张利方, 闰有功, 付丽萍, 等. 抗环瓜氨酸肽抗体及相关自身抗体在诊断类风湿性关节炎中的意义. 检验医学, 2006, 21(1): 12-14.
69.	张义东, 董宇鸿. IgM、IgG、IgA类类风湿因子及抗CCP抗体对RA的诊断意义. 临床检验杂志, 2006, 24(3): 205.
70.	赵超, 王雪. 抗环瓜氨酸肽抗体检测在类风湿性关节炎诊断中的临床价值. 实用医技杂志, 2006, 13(14): 2458-2459.
71.	赵雪, 姜晖. 抗环瓜氨酸肽抗体对类风湿关节炎的临床诊断价值. 黑龙江医学, 2006, 30(8).
72.	赵永新, 张铁汉, 张菁菁. 抗环瓜氨酸肽抗体、抗角质蛋白抗体和类风湿因子在类风湿关节炎诊断中的临床意义. 陕西医学杂志, 2006, 35(3): 335-336.
73.	朱海龙. 抗CCP抗体与RF联合检测在类风湿性关节炎诊断中的应用价值. 现代医药卫生, 2006, 22(11): 1593-1594.
74.	蔡细英, 袁柳, 谭慧清. AKA、APF、抗CCP检测在类风湿性关节炎诊断中的应用. 医学临床研究, 2005, 22(12): 1764-1765.
75.	陈雪娇, 吴春龙. 抗环瓜氨酸肽抗体在类风湿关节炎诊断中的临床应用. 中国现代实用医学杂志, 2005, 4(7): 15-17.
76.	程鹏飞, 刘元瑞. 类风湿关节炎早期标志物检测的临床评价. 武汉大学学报:医学版, 2005, 26(4): 529-532.
77.	戴辰程, 戴冽. 抗环瓜氨酸肽抗体检测在类风湿关节炎诊断中的价值. 广东医学, 2005, 26(6): 796-797.
78.	董巍, 张剑波. 抗环瓜氨酸肽抗体测定对类风湿关节炎诊断的临床价值. 实用医院临床杂志, 2005, 2(1): 84-86.
79.	韩玉祥, 邵福灵, 刘凤珍, 等. 类风湿关节炎患者抗环瓜氨酸肽抗体的测定及临床意义. 临床荟萃, 2005, 20(22): 1276-1278.
80.	雷小妹, 李守新. 抗CCP、抗RA33和RF在类风湿关节炎诊断中的作用. 临床内科杂志, 2005, 22(10): 667-668.
81.	李桂凤, 高锋. 类风湿性关节炎中抗环瓜氨酸肽抗体的检测. 现代检验医学杂志, 2005, 20(3): 7-10.
82.	李守勇, 张婷兰. 抗RA54抗体、抗CCP抗体、APF、AFA和RF联合检测诊断类风湿性关节炎的临床价值. 山东医药, 2005, 45(5): 25.
83.	刘升云, 高冠民. 抗环瓜氨酸肽抗体在风湿性多肌痛与老年发病类风湿关节炎鉴别诊断中的意义. 中华风湿病学杂志, 2005, 9(10): 631.
84.	刘云, 杨静. 抗环瓜氨酸肽抗体在类风湿性关节炎诊断中的应用评价. 川北医学院学报, 2005, 20(3): 327-329.
85.	刘泽有, 付艳丽, 刘晓娟, 等. 抗角蛋白抗体、抗环瓜氨酸多肽抗体在类风湿关节炎诊断中的应用. 实用诊断与治疗杂志, 2005, 19(1): 18-19.
86.	卢思俭, 邵璟. 抗环瓜氨酸肽抗体在类风湿关节炎诊断中的意义. 山西医药杂志, 2005, 34(7): 585-586.
87.	穆荣, 孙晓云, 栗占国. 类风湿因子和抗环瓜氨酸多肽抗体联合检测在类风湿关节炎诊断中的意义. 北京大学学报(医学版), 2005, 37(5): 498-500.
88.	倪丽萍, 陈琳. 血清抗环瓜氨酸肽抗体检测在类风湿性关节炎诊断中的应用. 中国交通医学杂志, 2005, 19(1).
89.	强红伟, 陈志伟, 顾美华, 等. 抗环瓜氨酸肽抗体在类风湿关节炎中的意义. 中国实用内科杂志, 2005, 25(12): 1105-1106.
90.	孙芸. 抗环瓜氨酸肽抗体检测在类风湿关节炎诊断中的意义. 江西医学检验, 2005, 23(4): 327-328.
91.	唐江涛, 王兰兰, 李立新, 等. 抗环瓜氨酸肽抗体在类风湿关节炎实验诊断中的应用评价. 四川大学学报(医学版), 2005, 36(5): 745-746.
92.	王亚强, 孙建华, 张锼, 等. ELISA法检测血清抗环瓜氨酸肽抗体在类风湿关节炎中的应用价值. 南京医科大学学报(自然科学版), 2005, 25(3): 215-216.
93.	吴春龙, 许玲鸽. AKA、RF及抗-CCP联合检测对类风湿性关节炎的诊断价值. 江西医学检验, 2005, 23(5): 389-401.
94.	吴敏, 谢雯, 马英淳. 抗环瓜氨酸肽抗体检测对老年人类风湿关节炎早期诊断价值的探讨. 实用临床医学(江西), 2005, 6(3): 4-6.
95.	吴茜. 抗环瓜氨酸肽抗体的检测及其临床意义. 现代检验医学杂志, 2005, 20(2): 64-65.
96.	吴盛海, 陈光. 联合检测类风湿因子和抗环瓜氨酸肽抗体在类风湿关节炎诊断中的价值. 浙江实用医学, 2005, 10(6): 381, 405.
97.	肖镇, 白丽杰, 秦毅强. AFA、抗CCP抗体RF对类风湿关节炎诊断及病情评估的意义. 内蒙古医学院学报, 2005, 27(4): 265-270.
98.	谢雯, 潘解萍. 抗环瓜氨酸肽抗体、抗角蛋白抗体和类风湿因子检测在类风湿关节炎中的临床意义. 临床荟萃, 2005, 20(5): 287-289.
99.	徐朝焰, 赵素萍. 抗环瓜氨酸肽抗体对类风湿关节炎的诊断意义. 中华风湿病学杂志, 2005, 9(11): 700-701.
100.	徐兆永, 戴艳. 抗CCP抗体与类风湿因子联合检测对类风湿性关节炎的临床意义. 皖南医学院学报, 2005, 24(3): 218-219.
101.	杨曙梅, 王惠民. 抗环瓜氨酸肽抗体的定量检测在类风湿性关节炎诊断中的应用. 江西医学检验, 2005, 23(1): 7-8.
102.	杨雅琼, 王毅, 张凯, 等. EDRA/CPA检测在类风湿性关节炎诊断中的应用. 天津医药, 2005, 33(7): 422-424.
103.	余芳, 费樱, 师萍. 抗环瓜氨酸肽抗体在类风湿性关节炎诊断中的应用评价. 贵州医药, 2005, 29(5): 409-411.
104.	曾智华, 钟亮尹. 抗环瓜氨酸肽抗体与RF联合检测在RA中的意义. 广州医药, 2005, 36(2): 64-66.
105.	张建明, 穆原. 116例类风湿性关节炎联合检测4种自身抗体的结果分析. 右江医学, 2005, 33(1): 3-5.
106.	张蜀澜, 李永哲, 佟大伟. 抗丝集蛋白抗体谱检测在类风湿性关节炎诊断中的临床意义. 中国医学检验杂志, 2005, 6(3): 177-179.
107.	张松照, 黄洪, 张颖, 等. 类风湿性关节炎患者抗环瓜氨酸肽抗体的临床应用. 上海医学, 2005, 28(12): 1040-1043.
108.	赵洪灿, 项国谦. RF、AKA和抗CCP抗体联检对类风湿关节炎诊断的临床价值. 放射免疫学杂志, 2005, 18(6): 499-501.
109.	蔡逸婷, 谢松业. 抗环瓜氨酸肽抗体检测对类风湿性关节炎临床诊断价值的探讨. 世界感染杂志, 2004, 4(4): 369-370,375.
110.	程艳杰, 王旭. 抗CCP、RA33抗体的检测在早期类风湿关节炎诊断中的应用. 中国医学检验杂志, 2004, 5(2): 90-93.
111.	刘光中. 抗环瓜氨酸肽抗体与类风湿因子联合检测在诊断类风湿性关节炎中的应用. 中国医药研究, 2004, 2(4): 22-23.
112.	吕宜爱, 李凤巧, 尚会燕. 类风湿关节炎患者抗-CCP抗体检测的临床意义. 哈尔滨医药, 2004, 24(5): 10-11.
113.	孟庆松, 刘小信, 杨宜娥. 四种抗体联合检测在类风湿关节炎早期诊断中的应用价值. 山东医药, 2004, 44(28): 1-3.
114.	钱龙, 李向培. 抗CCP抗体在类风湿关节炎诊断中的意义. 安徽医学, 2004, 25(3): 171-173.
115.	孙世俊. 抗环瓜氨酸肽抗体检测在类风湿关节炎中的意义. 第三军医大学学报, 2004, 26(19): 1786-1787.
116.	王伟, 杨肃文, 胡爱萍, 等. 类风湿性关节炎患者抗环瓜氨酸肽抗体检测的意义. 临床检验杂志, 2004, 22(3): 213.
117.	王勇, 方勇飞. 类风湿关节炎诊断中抗环瓜氨酸肽抗体与类风湿因子的意义. 中国临床康复, 2004, 8(9): 1616-1617.
118.	谢其冰, 刘钢. 抗环瓜氨酸肽抗体在类风湿关节炎诊断中的意义及对关节侵蚀预测的价值. 中华风湿病学杂志, 2004, 8(6): 356-360.
119.	姚敏, 王小敏. 抗环瓜氨酸抗体在类风湿性关节炎诊断的应用价值. 中国医学检验杂志, 2004, 5(6): 557-559.
120.	张华, 叶震璇. RF、抗RA33抗体、抗CCP抗体联合检测诊断类风湿关节炎的意义. 贵州医药, 2004, 28(1): 44-45.
121.	张建明, 丁玲华. 抗环瓜氨酸肽抗体及相关自身抗体在类风湿性关节炎诊断中的应用评价. 中国实验诊断学, 2004, 8(5): 513-516.
122.	张利方, 阎有功. 抗环瓜氨酸肽抗体在类风湿性关节炎诊断中的应用. 免疫学杂志, 2004, 20(1): 52-53, 57.
123.	钟亮尹, 曾智华. 抗CCP、抗RA33抗体与RF联合检测在RA中的意义. 实用医学杂志, 2004, 20(8): 952-953.
124.	周彬, 朱静. 抗环瓜氨酸肽抗体检测在类风湿关节炎中的诊断及预后意义探讨. 中华风湿病学杂志, 2004, 8(6): 360-362.
125.	崔天盆, 谢俊丽. 抗CCP、抗RA33等4种自身抗体在类风湿关节炎诊断中的应用. 上海医学检验杂志, 2003, 18(4): 221-222.
126.	胡学芳, 魏华. 抗环瓜氨酸肽抗体检测在类风湿关节炎诊断中的临床意义. 中华检验医学杂志, 2003, 26(8): 484-487.
127.	李峥, 毕胜. 四种血清抗体在类风湿关节炎中的诊断意义. 中国医学检验杂志, 2003, 4(6): 379-380.
128.	粱日初, 李跃进. 抗环瓜氨酸肽抗体检测与类风湿性关节炎早期诊断. 中国现代医学杂志, 2003, 13(13): 85-86, 89.
129.	王毅, 石姜, 程伟. 抗RA33、抗CCP抗体检测在RA诊断中的应用. 重庆医学, 2003, 32(8): 1033-1034.
130.	魏华, 李小峰. 抗环瓜氨酸肽抗体与抗Sa抗体联合检测对类风湿关节炎的意义. 中华风湿病学杂志, 2003, 7(10): 635-637.
131.	曾小峰, 艾脉兴. 抗环瓜氨酸肽抗体检测在类风湿关节炎中的意义. 中华风湿病学杂志, 2001, 5(5): 281-284.
132.	Liao KP, Batra KL, Chibnik L, et al. Anti-CCP revised criteria for the classification of rheumatoid arthritis. Ann Rheum Dis, 2008, 30.
133.	Narváez J, Sirvent E, Antonio Narváez J, et al. Usefulness of Magnetic Resonance Imaging of the Hand versus Anticyclic Citrullinated Peptide Antibody Testing to Confirm the Diagnosis of Clinically Suspected Early Rheumatoid Arthritis in the Absence of Rheumatoid Factor and Radiographic Erosions. Semin Arthritis Rheum, 2008, 24.
134.	Yamane T, Hashiramoto A, Tanaka Y, et al. Easy and Accurate Diagnosis of Rheumatoid Arthritis Using Anti-Cyclic Citrullinated Peptide 2 Antibody, Swollen Joint Count, and C-Reactive Protein/ Rheumatoid Factor. J Rheumatol, 2008, 35(3): 414-420.
135.	Alexiou I, Germenis A, Ziogas A, et al. Diagnostic value of anti-cyclic citrullinated peptide antibodies in Greek patients with rheumatoid arthritis. BMC Musculoskelet Disord, 2007,20(8):37.
136.	Ate A, Karaaslan Y, Aksaray S. Predictive value of antibodies to cyclic citrullinated peptide in patients with early arthritis. Clin Rheumatol, 2007, 26(4): 499-504.
137.	Inanc N, Dalkilic E, Kamali S, et al. Anti-CCP antibodies in rheumatoid arthritis and psoriatic arthritis. Clin Rheumatol, 2007, 26(1): 17-23.
138.	Koca SS, Akbulut H, Dag S, et al. Anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis and Behçet’s disease. Tohoku J Exp Med, 2007, 213(4): 297-304.
139.	Kudo-Tanaka E, Ohshima S, Ishii M, et al. Autoantibodies to cyclic citrullinated peptide 2 (CCP2) are superior to other potential diagnostic biomarkers for predicting rheumatoid arthritis in early undifferentiated arthritis. Clin Rheumatol, 2007, 26(10): 1627-33.
140.	Luis Caro-Oleas J, Fernández-Suárez A, Reneses Cesteros S, et al. Diagnostic usefulness of a third-generation anti-cyclic citrulline antibody test in patients with recent-onset polyarthritis. Clin Chem Lab Med, 2007, 45(10): 1396 - 1401.
141.	Lutteri L, Malaise M, Chapelle JP. Comparison of second- and thirdgeneration anti-cyclic citrullinated peptide antibodiesassays for detecting rheumatoid arthritis. Clin Chim Acta, 2007, 386(1-2): 76-81.
142.	Sghiri R, Bouagina E, Zaglaoui H, et al. Diagnostic performances of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis. Rheumatol Int, 2007,27(12):1125-30.
143.	Silveira IG, Burlingame RW, von Mühlen CA, et al. Anti-CCP antibodies have more diagnostic impact than rheumatoid factor (RF) in a population tested for RF. Clin Rheumatol, 2007, 26(11): 1883-1889.
144.	Soós L, Szekanecz Z, Szabó Z, et al. Clinical evaluation of antimutated citrullinated vimentin by ELISA in rheumatoid arthritis. J Rheumatol, 2007, 34(8): 1658-1663.
145.	Wu R, Shovman O, Zhang Y, et al. Increased prevalence of antithird generation cyclic citrullinated peptide antibodies in patients with rheumatoid arthritis and CREST syndrome. Clin Rev Allergy Immunol, 2007, 32(1): 47-56.
146.	Ceccato F, Roverano S, Barrionuevo A, et al. The role of anticyclic citrullinated peptide antibodies in the differential diagnosis of elderly-onset rheumatoid arthritis and Polymyalgia rheumatica. Clin Rheumatol, 2006, 25(6): 854-857.
147.	Dejaco C, Klotz W, Larcher H, et al. Diagnostic value of antibodies against a modified citrullinated vimentin in rheumatoid arthritis. Arthritis Res Ther, 2006, 8(4): 119.
148.	Hill JA, Al-Bishri J, Gladman DD, et al. Serum autoantibodies that bind citrullinated fibrinogen are frequently found in patients with rheumatoid arthritis. J Rheumatol, 2006, 33(11): 2115-2119.
149.	Korkmaz C, Us T, Kaifolu T, et al. Anti-cyclic citrullinated peptide (CCP) antibodies in patients with long-standing rheumatoid arthritis and their relationship with extra-articular manifestations. Clin Biochem, 2006, 39(10): 961-965.
150.	López-Longo FJ, Rodríguez-Mahou M, Sánchez-Ramón S, et al. Anti-cyclic citrullinated peptide versus anti-Sa antibodies in diagnosis of rheumatoid arthritis in an outpatient clinic for connective tissue disease and spondyloarthritis. J Rheumatol, 2006, 33(8): 1476-1481.
151.	Matsui T, Shimada K, Ozawa N, et al. Diagnostic utility of anti-cyclic citrullinated peptide antibodies for very early rheumatoid arthritis. J Rheumatol, 2006, 33(12): 2390-2397.
152.	Mikuls TR, Holers VM, Parrish L, et al. Anti-cyclic citrullinated peptide antibody and rheumatoid factor isotypes in African Americans with early rheumatoid arthritis. Arthritis Rheum, 2006, 54(9): 3057-3059.
153.	Panchagnula R, Rajiv SR, Prakash J, et al. Role of anticyclic citrullinated peptide in the diagnosis of early rheumatoid factornegative suspected rheumatoid arthritis: is it worthwhile to order the test? J Clin Rheumatol, 2006, 12(4): 172-175.
154.	Quinn MA, Gough AK, Green MJ, et al. Anti-CCP antibodies measured at disease onset help identify seronegative rheumatoid arthritis and predict radiological and functional outcome. Rheumatology (Oxford), 2006, 45(4): 478-480.
155.	Russell AS, Devani A, Maksymowych WP. The role of anti-cyclic citrullinated peptide antibodies in predicting progression of palindromic rheumatism to rheumatoid arthritis. J Rheumatol, 2006, 33(7): 1240 - 1242.
156.	Spadaro A, Riccieri V, Alessandri C, et al. [Usefulness of anti-cyclic citrullinate peptide antibodydetermination in synovial fluid analysis of patients with rheumatoid arthritis]. Reumatismo, 2006, 58(2): 116-120.
157.	van Venrooij WJ, Zendman AJW, Pruijn GJM. Autoantibodies to citrullinated antigens in (early) rheumatoid arthritis. Autoimmune, 2006, 6(1): 37-41.
158.	Abreu I, Laroche P, Bastos A, et al. Multiplexed immunoassay for detection of rheumatoid factors by FIDIS™ technology Ann. New York Acad Sci, 2005, 1050: 357 - 363.
159.	Aotsuka S, Okawa-Takatsuji M, Nagatani K, et al. A retrospective study of the fluctuation in serum levels of anti-cyclic citrullinated peptide antibody in patients with rheumatoid arthritis. Clin Exp Rheumatol, 2005, 23(4): 475-481.
160.	Choi SW, Lim MK, Shin DH, et al. Diagnostic performances of anticyclic citrullinated peptides antibody and antifilaggrin antibody in Korean patients with rheumatoid arthritis. J Korean Med Sci, 2005, 20(3): 473-478.
161.	Fernández-Suárez A, Reneses S, Wichmann I, et al. Efficacy of three ELISA measurements of anti-cyclic citrullinated peptide antibodies in the early diagnosis of rheumatoid arthritis. Clin Chem Lab Med, 2005, 43(11): 1234-1239.
162.	García-Berrocal B, González C, Pérez M, et al. Anti-cyclic citrullinated peptide autoantibodies in IgM rheumatoid factorpositive patients. Clin Chim Acta, 2005, 354(1-2): 123-130.
163.	Greiner A, Plischke H, Kellner H, et al. Association of anti-cyclic citrullinated peptide antibodies, anti-citrullin antibodies, and IgM and IgA rheumatoid factors with serological parameters of disease activity in rheumatoid arthritis. Ann N Y Acad Sci, 2005, 1050: 295-303.
164.	Kamali S, Polat NG, Kasapoglu E, et al. Anti-CCP and antikeratin antibodies in rheumatoid arthritis, primary Sjögren’s syndrome, and Wegener’s granulomatosis. Clin Rheumatol, 2005, 24(6): 673-676.
165.	Korendowych E, Owen P, Ravindran J, et al. The clinical and genetic associations of anti-cyclic citrullinated peptide antibodies in psoriatic arthritis. Rheumatology, 2005, 44(8): 1056-1060.
166.	Kwok JS, Hui KH, Lee TL, et al. Anti-cyclic citrullinated peptide: diagnostic and prognostic values in juvenile idiopathic arthritis and rheumatoid arthritis in a Chinese population. Scand J Rheumatol, 2005, 34(5): 359-366.
167.	Nell VP, Machold KP, Stamm TA, et al. Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis. Ann Rheum Dis, 2005, 64(12): 1731-1736.
168.	Nielen MM, van der Horst AR, van Schaardenburg D, et al. Antibodies to citrullinated human fibrinogen (ACF) have diagnostic and prognostic value in early arthritis. Ann Rheum Dis, 2005, 64(8): 1199-1204.
169.	Raza K, Breese M, Nightingale P, et al. Predictive value of antibodies to cyclic citrullinated peptide in patients with very early inflammatory arthritis. J Rheumatol, 2005, 32(2): 231-238.
170.	Sauerland U, Becker H, Seidel M, et al. Clinical utility of the anti-CCP assay: experiences with 699 patients. Ann N Y Acad Sci, 2005, 1050: 314-318.
171.	Tampoia M, Brescia V, Fontana A, et al. Anti-cyclic citrullinated peptide autoantibodies measured by an automated enzyme immunoassay: analytical performance and clinical correlations. Clin Chim Acta, 2005, 355(1-2): 137-144.
172.	van Gaalen FA, Visser H, Huizinga TW. A comparison of the diagnostic accuracy and prognostic value of the first and second anticyclic citrullinated peptides (CCP1 and CCP1) autoantibody tests for rheumatoid arthritis. Ann Rheum Dis, 2005, 64(10): 1510-1512.
173.	Berglin E, Padyukov L, Sundin U, et al. A combination of autoantibodies to cyclic citrullinated peptide (CCP) and HLA-DRB0 locus antigens is strongly associated with future onset of rheumatoid arthritis. Arthritis Res Ther, 2004, 6(4): 303-308.
174.	Bombardieri M, Alessandri C, Labbadia G, et al. Valesini G Role of anti-cyclic citrullinated peptide antibodies in discriminating patients with rheumatoid arthritis from patients with chronic hepatitis C infection-associated polyarticular involvement. Arthritis Res Ther, 2004, 6(2): 137-141.
175.	Bongi SM, Manetti R, Melchiorre D, et al. Anti-cyclic citrullinated peptide antibodies are highly associated with severe bone lesions in rheumatoid arthritis anti-CCP and bone damage in RA. Autoimmunity, 2004, 37(6-7): 495-501.
176.	Correa PA, Tobón GJ, Citera G, et al. [Anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis: relation with clinical features, cytokines and HLA-DRB0]. Biomedica, 2004, 24(2): 140-152.
177.	De Rycke L, Peene I, Hoffman IE, et al. Rheumatoid factor and anticitrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate, and extraarticular manifestations. Ann Rheum Dis, 2004, 63(12): 1587-1593.
178.	Dubucquoi S, Solau-Gervais E, Lefranc D, et al. Evaluation of anticitrullinated filaggrin antibodies as hallmarks for the diagnosis of rheumatic diseases. Ann Rheum Dis, 2004, 63(4): 415-419.
179.	Girelli F, Foschi FG, Bedeschi E, et al. Is Anti Cyclic citrullinated peptide a useful laboratory test for the diagnosis of rheumatoid arthritis? Eur Ann Allergy Clin Immunol, 2004, 36(4): 127-130.
180.	Grootenboer-Mignot S, Nicaise-Roland P, Delaunay C, et al. Second generation anti-cyclic citrullinated peptide (anti-CCP1) antibodies can replace other anti-filaggrin antibodies and improve rheumatoid arthritis diagnosis. Scand J Rheumatol, 2004, 33(4): 218-220.
181.	Hitchon CA, Alex P, Erdile LB, et al. A distinct multicytokine profile is associated with anti-cyclical citrullinated peptide antibodies in patients with early untreated inflammatory arthritis. J Rheumatol, 2004, 31(12): 2336-2346.
182.	Jansen TL, Bruyn GA. Diagnostic value of antcyclic citrullinated peptide antibody in rheumatoid arthritis. J Rheumatol, 2004, 31(5): 1012-1013.
183.	Lopez-Hoyos M, Ruiz de Alegria C, Blanco R, et al. Clinical utility of anti-CCP antibodies in the differential diagnosis of elderly-onset rheumatoid arthritis and Polymyalgia rheumatica. Rheumatology (Oxford), 2004, 43(5): 655-657.
184.	Söderlin MK, Kastbom A, Kautiainen H, et al. Antibodies against cyclic citrullinated peptide (CCP) and levels of cartilage oligomeric matrix protein (COMP) in very early arthritis: relation to diagnosis and disease activity. Scand J Rheumatol, 2004, 33(3): 185-188.
185.	Vallbracht I, Rieber J, Oppermann M, et al. Diagnostic and clinical value of anti-cyclic citrullinated peptide antibodies compared with rheumatoid factor isotypes in rheumatoid arthritis. Ann Rheum Dis, 2004, 63(9): 1079-1084.
186.	van Venrooij WJ, Vossenaar ER, Zendman AJ Anti-CCP antibodies: the new rheumatoid factor in the serology ofrheumatoid arthritis. Autoimmun Rev, 2004, 3(1): 17-19.
187.	Vittecoq O, Incaurgarat B, Jouen-Beades F, et al. Autoantibodies recognizing citrullinated rat filaggrin in an ELISA using citrullinated and non-citrullinated recombinant proteins as antigens are highly diagnostic for rheumatoid arthritis. Clin Exp Immunol, 2004, 135(1): 173-180.
188.	Bas S, Genevay S, Meyer O, et al. Anti-cyclic citrullinated peptide antibodies, IgM and IgA rheumatoid factors in the diagnosis and prognosis of rheumatoid arthritis. Rheumatology (Oxford), 2003, 42(5): 677-680.
189.	Jansen LM, van Schaardenburg D, van der Horst-Bruinsma I, et al. The predictive value of anti-cyclic citrullinated peptide antibodies in early arthritis. J Rheumatol, 2003, 30(8): 1691-1695.
190.	Lee DM, Schur PH. Clinical utility of the anti-CCP assay in patients with rheumatic diseases. Ann Rheum Dis, 2003, 62(9): 870-874.
191.	Rantapää-Dahlqvist S, de Jong BA, Berglin E, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum, 2003, 48(10): 2741-2749.
192.	Saraux A, Berthelot JM, Devauchelle V, et al. Value of antibodies to citrulline-containing peptides for diagnosing early rheumatoid arthritis. J Rheumatol, 2003, 30(12): 2535-2539.
193.	Suzuki K, Sawada T, Murakami A, et al. High diagnostic performance of ELISA detection of antibodies to citrullinated antigens in rheumatoid arthritis. Scand J Rheumatol, 2003, 32(4): 197-204.
194.	Zeng X, Ai M, Tian X, et al. Diagnostic value of anti-cyclic citrullinated Peptide antibody in patients with rheumatoid arthritis. J Rheumatol, 2003, 30(7): 1451-1455.
195.	Bas S, Perneger TV, Seitz M, et al. Diagnostic tests for rheumatoid arthritis: comparison of anti-cyclic citrullinated peptide antibodies, anti-keratin antibodies and IgM rheumatoid factors. Rheumatology (Oxford), 2002, 41(7): 809-814.
196.	Jansen AL, van der Horst-Bruinsma I, van Schaardenburg D, et al. Rheumatoid factor and antibodies to cyclic citrullinated Peptide differentiate rheumatoid arthritis from undifferentiated polyarthritis in patients with early arthritis. J Rheumatol, 2002, 29(10): 2074-2076.
197.	Vincent C, Nogueira L, Sebbag M, et al. Detection of antibodies to deiminated recombinant rat filaggrin by enzyme-linked immunosorbent assay: a highly effective test for the diagnosis of rheumatoid arthritis. Arthritis Rheum, 2002, 46(8): 2051-2058.
198.	Bizzaro N, Mazzanti G, Tonutti E, et al. Diagnostic accuracy of the anti-citrulline antibody assay for rheumatoid arthritis. Clin Chem, 2001, 47(6): 1089-1093.
199.	Goldbach-Mansky R, Lee J, McCoy A, et al. Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset. Arthritis Res, 2000, 2(3): 236-243.
200.	Schellekens GA, Visser H, de Jong BA, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum, 2000, 43(1): 155-163.

1. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum, 1988, 31: 315-324.
2. Masura J, Walsh KP, Thanopoulous B, et al. Catheter closure of moderate to large-sized patient ductus arteriosus using the new Amplatzer Duct Occluder:Immediate and short-term results. J Am Coll Cardiol, 1998, 31: 878-882.
3. Sehellekens GA, Visser H, De Jong BA, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullonated peptide. Arthritis Rheum, 2000, 43: 155-163.
4. Whiting PF, Weswood ME, Rutjes AW, et al. Evaluation of QUADAS, a tool for the quality assessment of diagnostic accuracy studies. BMC Med Res Methodol, 2006, 6: 9.
5. Patrick M, Bossuyt JB, Reitsma DE, et al. The STARD statement for reporting studies of diagnosis accuracy: explanation and elaboration. Croat Med J, 2003, 44: 639-650.
6. 陈华丽, 杨文东, 韩景银. 抗CCP抗体与RF联合检测诊断类风湿关节炎的价值. 齐鲁医学杂志, 2007, 22(6): 508-510.
7. 陈红梅, 孙明忠. 抗环瓜氨酸肽抗体与RF联合检测在RA诊断中的应用. 现代检验医学杂志, 2007, 22(4): 79-80.
8. 陈俊伟, 李小峰. 抗环瓜氨酸肽抗体在风湿性疾病中的意义. 基层医学论坛, 2007, 11(8): 668-669.
9. 符克英, 陈汝, 占锋, 等. 类风湿因子、AKA和抗CCP抗体检测在类风湿关节炎的诊断价值. 中国热带医学, 2007, 7(11): 2029-2030.
10. 顾福荣, 张义东. 抗CCP抗体、抗RA33抗体、抗Sa抗体和RF联合检测对类风湿性关节炎诊断的意义. 江西医学检验, 2007, 25(1): 24-25.
11. 胡学亭, 夏祥阶, 魏红, 等. 血清抗环瓜氨酸肽抗体和类风湿因子联合检测对类风湿性关节炎的诊断价值. 潍坊医学院学报, 2007, 29(1): 57-58.
12. 胡志东, 吕军强. 抗环瓜氨酸肽抗体和血管内皮生长因子对类风湿关节炎实验诊断意义探讨. 检验医学, 2007, 22(1): 41-43.
13. 乐爱平, 鞠北华, 黄清水, 等.Ⅰ型胶原吡啶交联终肽及抗环瓜氨酸肽抗体等联合检测在类风湿关节炎诊断与病情监测中的应用. 中国实用内科杂志, 2007, 27(23): 1852-1855.
14. 李芳, 许立飞. 抗环瓜氨酸肽抗体在类风湿关节炎中的诊断和鉴别诊断价值. 中国医师进修杂志内科版, 2007, 30(9): 37.
15. 李光迪, 刘芳. 抗环瓜氨酸肽抗体与类风湿因子IgM联合检测在类风湿关节炎早期诊断中的应用. 国际检验医学杂志, 2007, 28(8): 696-698.
16. 刘喜德, 蔡龙, 李召东, 等. 抗环瓜氨酸肽抗体在类风湿关节炎诊断中的意义. 浙江中西医结合杂志, 2007, 17(1): 8-10.
17. 卢芝君, 俞松山. 抗环瓜氨酸肽抗体检测在类风湿性关节炎早期诊断中的临床意义. 全科医学临床与教育, 2007, 5(3): 242-243.
18. 穆春晓. 类风湿关节炎诊断中RF、AKA及抗CCP抗体联检的临床价值. 医学理论与实践, 2007, 20(5): 517-518.
19. 秦白茹, 王亚强. 血清抗环瓜氨酸肽抗体检测在类风湿关节炎中的诊断价值. 现代预防医学, 2007, 34(2): 346.
20. 石宏宴. 抗CCP抗体与RF联合检测在类风湿关节炎中的临床意义. 中国实用医药, 2007, 2(2): 116-117.
21. 宋继军, 潘秀军, 岳晓红. 抗环瓜氨酸肽抗体对类风湿性关节炎诊断的应用价值. 职业与健康, 2007, 23(22): 2020-2021.
22. 宋欣丽, 王颖. 抗环瓜氨酸肽抗体检测在类风湿关节炎中的诊断意义. 陕西医学杂志, 2007, 36(7): 882-883.
23. 苏锡康. 抗环瓜氨酸肽抗体、抗角质蛋白抗体和类风湿因子在类风湿性关节炎诊断中的意义. 江西医学检验, 2007, 25(2): 129-130.
24. 汤卫菊. 抗环状瓜氨酸肽(CCP)抗体检测的临床应用. 中国医药导报, 2007, 4(11).
25. 王丹彤, 陈亮. 抗环瓜氨酸肽抗体、抗角蛋白抗体在类风湿关节炎中的临床意义. 内蒙古医学杂志, 2007, 39(7): 797-798.
26. 王海, 李瑞清, 何建发, 等. 抗环瓜氨酸多肽抗体和类风湿因子联合检测在早期类风湿关节炎诊断中的意义. 实用医学杂志, 2007, 23(13): 2003-2004.
27. 王军, 文爱清. 抗环瓜氨酸肽抗体对类风湿关节炎诊断的临床评价. 重庆医学, 2007, 36(15): 1513-1515.
28. 王嫱, 左晓霞, 游运辉, 等. 抗环瓜氨酸肽抗体在类风湿性关节炎中的检测及临床研究. 中国现代医学杂志, 2007, 17(13): 1645-1648.
29. 王世强. 类风湿性关节炎患者血清抗环瓜氨酸肽抗体的检测分析. 中华临床医学研究杂志, 2007, 13(16): 2420-2421.
30. 王永福, 康丽荣. 联合检测抗环瓜氨酸肽抗体及抗角蛋白抗体在类风湿关节炎患者中的临床意义. 内蒙古医学杂志, 2007, 39(2): 131-132.
31. 韦薇, 钱雅琴. 抗体联合检测在类风湿关节炎早期诊断中的临床意义. 贵州医药, 2007, 31(5): 401-403.
32. 巫翠萍, 覃西. RF、抗-CCP和AKA联合检测在类风湿性关节炎诊断中的价值. 中国热带医学, 2007, 7(8): 1367-1368.
33. 许超尘, 饶华春, 游玉权, 等. 联合检测AKA、抗CCP抗体与RF在类风湿性关节炎诊断中的应用. 中国现代医药杂志, 2007, 9(11): 43-45.
34. 徐惠萍, 齐文成. 抗环瓜氨酸肽抗体在类风湿性关节炎诊断中的研究. 国际医药卫生导报, 2007, 13(4): 14-17.
35. 严利文, 李晶. 抗环瓜氨酸肽抗体在类风湿关节炎中的诊断意义. 江苏大学学报: 医学版, 2007, 17(2): 164-166.
36. 杨春莉, 裘宇容. 对比检测血清中抗环瓜氨酸肽抗体水平对类风湿关节炎的诊断价值. 南方医科大学学报, 2007, 27(8): 1277-1278.
37. 杨平, 杭永论. 抗CCP抗体与RF联合检测在类风湿关节炎早期诊断中的价值. 山东医药, 2007, 47(5).
38. 姚小平. 抗环瓜氨酸肽抗体在类风湿性关节炎诊断和治疗中的应用. 临床和实验医学杂志, 2007, 6(3): 21-22.
39. 蔡文虹, 孙保东, 洪小平, 等. RF、CCP和AKA联合检测在类风湿关节炎诊断中的评价. 临床和实验医学杂志, 2006, 5(6): 671-672.
40. 曹德华, 于虹. 类风湿性关节炎108例血清抗环瓜氨酸肽抗体的检测. 中国误诊学杂志, 2006, 6(8): 1454-1455.
41. 陈敏静, 李珩. 联合检测三种自身免疫抗体在早期类风湿关节炎诊断中的意义. 现代医院, 2006, 6(3): 60-61.
42. 陈晓玲, 潘莎琳. CCP抗体和RF在类风湿性关节炎诊断中的应用. 四川医学, 2006, 27(7): 690-691.
43. 崔华东, 张宁. 抗环瓜氨酸多肽抗体检测早期诊断类风湿关节炎研究. 中国实用内科杂志, 2006, 26(24): 1977-1978.
44. 崔奕文, 鲁荣兵. 类风湿关节炎患者抗-CCP抗体检测的临床意义. 国际检验医学杂志, 2006, 27(10): 949.
45. 顾猛, 丁小兰. 应用ROC曲线分析评价抗环瓜氨酸肽抗体对类风湿性关节炎的诊断价值. 中国现代实用医学杂志, 2006, 5(7): 11-14.
46. 韩玉祥, 邵福灵, 靳洪涛, 等. 抗环瓜氨酸肽抗体在类风湿关节炎诊断中的应用. 中国误诊学杂志, 2006, 6(5): 810-812.
47. 胡清, 王芳, 孙明锦, 等. 抗CCP抗体和抗RA33抗体对老年类风湿关节炎诊断的意义. 中国老年学杂志, 2006, 26(2): 182-183.
48. 赖战峰, 吴晓宁. 抗环瓜氨酸肽抗体定量检测在类风湿关节炎中的诊断价值. 广西医科大学学报, 2006, 23(6): 985-986.
49. 李桂凤, 高峰. 血清中第二代抗环瓜氨酸肽抗体水平的检测在类风湿关节炎中的诊断价值. 中国实验诊断学, 2006, 10(1): 84-87.
50. 李世荣, 马金栋, 王云增, 等. 类风湿性关节炎患者检测抗CCP抗体、抗RA33抗体、CRP的临床价值. 临床检验杂志, 2006, 24(4): 270, 273.
51. 李小龙, 陶洪群. 抗环瓜氨酸肽抗体在类风湿性关节炎诊断中的应用. 检验医学, 2006, 21(6): 599-601.
52. 梁建群, 罗燕飞. 早期类风湿关节炎指标的评价. 实用医学杂志, 2006, 22(15): 1820-1821.
53. 林玲, 肖征宇, 陈肃标, 等. 抗环瓜氨酸肽抗体在类风湿关节炎中的意义. 中国卫生检验杂志, 2006, 16(5): 516-518.
54. 刘黎. 关节液中抗环瓜氨酸肽抗体在类风湿关节炎诊断和评估中的意义. 诊断学理论与实践, 2006, 5(4): 301-303.
55. 孟庆松, 刘小信, 杨宜娥, 等. AKA、APF、RF和抗CCP抗体在类风湿关节炎诊断和鉴别诊断中的应用. 医学检验与临床 2006, 17(6): 35-37.
56. 潘解萍, 谢雯. 抗环瓜氨酸肽抗体在类风湿关节炎早期诊断中的临床意义. 江苏医药, 2006, 32(1): 68-69.
57. 彭晓东, 李立新. 抗CCP抗体、AKA及RF对类风湿性关节炎的诊断价值. 四川大学学报(医学版), 2006, 37(2): 317-318.
58. 任天丽, 石国勋. 血清抗环瓜氨酸肽抗体在类风湿关节炎诊断中的评价. 诊断学理论与实践, 2006, 5(4): 304-305.
59. 谭立明, 彭卫华. 抗环瓜氨酸肽抗体检测在类风湿性关节炎的临床应用研究. 江西医学检验, 2006, 24(4): 312-314.
60. 唐吉斌, 孙芸. 抗CCP抗体与RF联合检测在类风湿关节炎早期诊断中的意义. 检验医学与临床, 2006, 3(1): 12-14.
61. 王剑英, 李萍, 王伟刚. 抗环瓜氨酸肽抗体等四种抗体在早期类风湿关节炎诊断中的意义. 中国实验诊断学, 2006, 10(12): 1446-1448.
62. 王友莲, 胡坚方. 抗环瓜氨酸肽抗体检测对类风湿关节炎的诊断意义. 实用临床医学(江西), 2006, 7(6).
63. 肖长虹, 吴启富. 类风湿关节炎关节液抗环瓜氨酸肽抗体的检测及意义. 中华风湿病学杂志, 2006, 10(3): 184-186.
64. 肖镇, 王勇, 秦毅强, 等. 抗环瓜氨酸肽抗体等三种抗体在类风湿关节炎中的诊断价值. 临床荟萃, 2006, 21(19): 1406-1408.
65. 肖镇, 白丽杰, 秦毅强. 联合检测AFA与抗CCP抗体RF对评估类风湿关节炎的临床意义. 内蒙古医学杂志, 2006, 38(1): 9-12.
66. 余伟, 朱梅英. 抗环瓜氨酸肽抗体、类风湿因子与抗角蛋白抗体在类风湿关节炎诊断中的价值比较. 检验医学, 2006, 21(2): 103-105.
67. 曾瑜, 陈明. 抗环瓜氨酸肽抗体和类风湿因子联合测定对类风湿关节炎的诊断价值. 中国临床医学, 2006, 13(6): 1022-1023.
68. 张利方, 闰有功, 付丽萍, 等. 抗环瓜氨酸肽抗体及相关自身抗体在诊断类风湿性关节炎中的意义. 检验医学, 2006, 21(1): 12-14.
69. 张义东, 董宇鸿. IgM、IgG、IgA类类风湿因子及抗CCP抗体对RA的诊断意义. 临床检验杂志, 2006, 24(3): 205.
70. 赵超, 王雪. 抗环瓜氨酸肽抗体检测在类风湿性关节炎诊断中的临床价值. 实用医技杂志, 2006, 13(14): 2458-2459.
71. 赵雪, 姜晖. 抗环瓜氨酸肽抗体对类风湿关节炎的临床诊断价值. 黑龙江医学, 2006, 30(8).
72. 赵永新, 张铁汉, 张菁菁. 抗环瓜氨酸肽抗体、抗角质蛋白抗体和类风湿因子在类风湿关节炎诊断中的临床意义. 陕西医学杂志, 2006, 35(3): 335-336.
73. 朱海龙. 抗CCP抗体与RF联合检测在类风湿性关节炎诊断中的应用价值. 现代医药卫生, 2006, 22(11): 1593-1594.
74. 蔡细英, 袁柳, 谭慧清. AKA、APF、抗CCP检测在类风湿性关节炎诊断中的应用. 医学临床研究, 2005, 22(12): 1764-1765.
75. 陈雪娇, 吴春龙. 抗环瓜氨酸肽抗体在类风湿关节炎诊断中的临床应用. 中国现代实用医学杂志, 2005, 4(7): 15-17.
76. 程鹏飞, 刘元瑞. 类风湿关节炎早期标志物检测的临床评价. 武汉大学学报:医学版, 2005, 26(4): 529-532.
77. 戴辰程, 戴冽. 抗环瓜氨酸肽抗体检测在类风湿关节炎诊断中的价值. 广东医学, 2005, 26(6): 796-797.
78. 董巍, 张剑波. 抗环瓜氨酸肽抗体测定对类风湿关节炎诊断的临床价值. 实用医院临床杂志, 2005, 2(1): 84-86.
79. 韩玉祥, 邵福灵, 刘凤珍, 等. 类风湿关节炎患者抗环瓜氨酸肽抗体的测定及临床意义. 临床荟萃, 2005, 20(22): 1276-1278.
80. 雷小妹, 李守新. 抗CCP、抗RA33和RF在类风湿关节炎诊断中的作用. 临床内科杂志, 2005, 22(10): 667-668.
81. 李桂凤, 高锋. 类风湿性关节炎中抗环瓜氨酸肽抗体的检测. 现代检验医学杂志, 2005, 20(3): 7-10.
82. 李守勇, 张婷兰. 抗RA54抗体、抗CCP抗体、APF、AFA和RF联合检测诊断类风湿性关节炎的临床价值. 山东医药, 2005, 45(5): 25.
83. 刘升云, 高冠民. 抗环瓜氨酸肽抗体在风湿性多肌痛与老年发病类风湿关节炎鉴别诊断中的意义. 中华风湿病学杂志, 2005, 9(10): 631.
84. 刘云, 杨静. 抗环瓜氨酸肽抗体在类风湿性关节炎诊断中的应用评价. 川北医学院学报, 2005, 20(3): 327-329.
85. 刘泽有, 付艳丽, 刘晓娟, 等. 抗角蛋白抗体、抗环瓜氨酸多肽抗体在类风湿关节炎诊断中的应用. 实用诊断与治疗杂志, 2005, 19(1): 18-19.
86. 卢思俭, 邵璟. 抗环瓜氨酸肽抗体在类风湿关节炎诊断中的意义. 山西医药杂志, 2005, 34(7): 585-586.
87. 穆荣, 孙晓云, 栗占国. 类风湿因子和抗环瓜氨酸多肽抗体联合检测在类风湿关节炎诊断中的意义. 北京大学学报(医学版), 2005, 37(5): 498-500.
88. 倪丽萍, 陈琳. 血清抗环瓜氨酸肽抗体检测在类风湿性关节炎诊断中的应用. 中国交通医学杂志, 2005, 19(1).
89. 强红伟, 陈志伟, 顾美华, 等. 抗环瓜氨酸肽抗体在类风湿关节炎中的意义. 中国实用内科杂志, 2005, 25(12): 1105-1106.
90. 孙芸. 抗环瓜氨酸肽抗体检测在类风湿关节炎诊断中的意义. 江西医学检验, 2005, 23(4): 327-328.
91. 唐江涛, 王兰兰, 李立新, 等. 抗环瓜氨酸肽抗体在类风湿关节炎实验诊断中的应用评价. 四川大学学报(医学版), 2005, 36(5): 745-746.
92. 王亚强, 孙建华, 张锼, 等. ELISA法检测血清抗环瓜氨酸肽抗体在类风湿关节炎中的应用价值. 南京医科大学学报(自然科学版), 2005, 25(3): 215-216.
93. 吴春龙, 许玲鸽. AKA、RF及抗-CCP联合检测对类风湿性关节炎的诊断价值. 江西医学检验, 2005, 23(5): 389-401.
94. 吴敏, 谢雯, 马英淳. 抗环瓜氨酸肽抗体检测对老年人类风湿关节炎早期诊断价值的探讨. 实用临床医学(江西), 2005, 6(3): 4-6.
95. 吴茜. 抗环瓜氨酸肽抗体的检测及其临床意义. 现代检验医学杂志, 2005, 20(2): 64-65.
96. 吴盛海, 陈光. 联合检测类风湿因子和抗环瓜氨酸肽抗体在类风湿关节炎诊断中的价值. 浙江实用医学, 2005, 10(6): 381, 405.
97. 肖镇, 白丽杰, 秦毅强. AFA、抗CCP抗体RF对类风湿关节炎诊断及病情评估的意义. 内蒙古医学院学报, 2005, 27(4): 265-270.
98. 谢雯, 潘解萍. 抗环瓜氨酸肽抗体、抗角蛋白抗体和类风湿因子检测在类风湿关节炎中的临床意义. 临床荟萃, 2005, 20(5): 287-289.
99. 徐朝焰, 赵素萍. 抗环瓜氨酸肽抗体对类风湿关节炎的诊断意义. 中华风湿病学杂志, 2005, 9(11): 700-701.
100. 徐兆永, 戴艳. 抗CCP抗体与类风湿因子联合检测对类风湿性关节炎的临床意义. 皖南医学院学报, 2005, 24(3): 218-219.
101. 杨曙梅, 王惠民. 抗环瓜氨酸肽抗体的定量检测在类风湿性关节炎诊断中的应用. 江西医学检验, 2005, 23(1): 7-8.
102. 杨雅琼, 王毅, 张凯, 等. EDRA/CPA检测在类风湿性关节炎诊断中的应用. 天津医药, 2005, 33(7): 422-424.
103. 余芳, 费樱, 师萍. 抗环瓜氨酸肽抗体在类风湿性关节炎诊断中的应用评价. 贵州医药, 2005, 29(5): 409-411.
104. 曾智华, 钟亮尹. 抗环瓜氨酸肽抗体与RF联合检测在RA中的意义. 广州医药, 2005, 36(2): 64-66.
105. 张建明, 穆原. 116例类风湿性关节炎联合检测4种自身抗体的结果分析. 右江医学, 2005, 33(1): 3-5.
106. 张蜀澜, 李永哲, 佟大伟. 抗丝集蛋白抗体谱检测在类风湿性关节炎诊断中的临床意义. 中国医学检验杂志, 2005, 6(3): 177-179.
107. 张松照, 黄洪, 张颖, 等. 类风湿性关节炎患者抗环瓜氨酸肽抗体的临床应用. 上海医学, 2005, 28(12): 1040-1043.
108. 赵洪灿, 项国谦. RF、AKA和抗CCP抗体联检对类风湿关节炎诊断的临床价值. 放射免疫学杂志, 2005, 18(6): 499-501.
109. 蔡逸婷, 谢松业. 抗环瓜氨酸肽抗体检测对类风湿性关节炎临床诊断价值的探讨. 世界感染杂志, 2004, 4(4): 369-370,375.
110. 程艳杰, 王旭. 抗CCP、RA33抗体的检测在早期类风湿关节炎诊断中的应用. 中国医学检验杂志, 2004, 5(2): 90-93.
111. 刘光中. 抗环瓜氨酸肽抗体与类风湿因子联合检测在诊断类风湿性关节炎中的应用. 中国医药研究, 2004, 2(4): 22-23.
112. 吕宜爱, 李凤巧, 尚会燕. 类风湿关节炎患者抗-CCP抗体检测的临床意义. 哈尔滨医药, 2004, 24(5): 10-11.
113. 孟庆松, 刘小信, 杨宜娥. 四种抗体联合检测在类风湿关节炎早期诊断中的应用价值. 山东医药, 2004, 44(28): 1-3.
114. 钱龙, 李向培. 抗CCP抗体在类风湿关节炎诊断中的意义. 安徽医学, 2004, 25(3): 171-173.
115. 孙世俊. 抗环瓜氨酸肽抗体检测在类风湿关节炎中的意义. 第三军医大学学报, 2004, 26(19): 1786-1787.
116. 王伟, 杨肃文, 胡爱萍, 等. 类风湿性关节炎患者抗环瓜氨酸肽抗体检测的意义. 临床检验杂志, 2004, 22(3): 213.
117. 王勇, 方勇飞. 类风湿关节炎诊断中抗环瓜氨酸肽抗体与类风湿因子的意义. 中国临床康复, 2004, 8(9): 1616-1617.
118. 谢其冰, 刘钢. 抗环瓜氨酸肽抗体在类风湿关节炎诊断中的意义及对关节侵蚀预测的价值. 中华风湿病学杂志, 2004, 8(6): 356-360.
119. 姚敏, 王小敏. 抗环瓜氨酸抗体在类风湿性关节炎诊断的应用价值. 中国医学检验杂志, 2004, 5(6): 557-559.
120. 张华, 叶震璇. RF、抗RA33抗体、抗CCP抗体联合检测诊断类风湿关节炎的意义. 贵州医药, 2004, 28(1): 44-45.
121. 张建明, 丁玲华. 抗环瓜氨酸肽抗体及相关自身抗体在类风湿性关节炎诊断中的应用评价. 中国实验诊断学, 2004, 8(5): 513-516.
122. 张利方, 阎有功. 抗环瓜氨酸肽抗体在类风湿性关节炎诊断中的应用. 免疫学杂志, 2004, 20(1): 52-53, 57.
123. 钟亮尹, 曾智华. 抗CCP、抗RA33抗体与RF联合检测在RA中的意义. 实用医学杂志, 2004, 20(8): 952-953.
124. 周彬, 朱静. 抗环瓜氨酸肽抗体检测在类风湿关节炎中的诊断及预后意义探讨. 中华风湿病学杂志, 2004, 8(6): 360-362.
125. 崔天盆, 谢俊丽. 抗CCP、抗RA33等4种自身抗体在类风湿关节炎诊断中的应用. 上海医学检验杂志, 2003, 18(4): 221-222.
126. 胡学芳, 魏华. 抗环瓜氨酸肽抗体检测在类风湿关节炎诊断中的临床意义. 中华检验医学杂志, 2003, 26(8): 484-487.
127. 李峥, 毕胜. 四种血清抗体在类风湿关节炎中的诊断意义. 中国医学检验杂志, 2003, 4(6): 379-380.
128. 粱日初, 李跃进. 抗环瓜氨酸肽抗体检测与类风湿性关节炎早期诊断. 中国现代医学杂志, 2003, 13(13): 85-86, 89.
129. 王毅, 石姜, 程伟. 抗RA33、抗CCP抗体检测在RA诊断中的应用. 重庆医学, 2003, 32(8): 1033-1034.
130. 魏华, 李小峰. 抗环瓜氨酸肽抗体与抗Sa抗体联合检测对类风湿关节炎的意义. 中华风湿病学杂志, 2003, 7(10): 635-637.
131. 曾小峰, 艾脉兴. 抗环瓜氨酸肽抗体检测在类风湿关节炎中的意义. 中华风湿病学杂志, 2001, 5(5): 281-284.
132. Liao KP, Batra KL, Chibnik L, et al. Anti-CCP revised criteria for the classification of rheumatoid arthritis. Ann Rheum Dis, 2008, 30.
133. Narváez J, Sirvent E, Antonio Narváez J, et al. Usefulness of Magnetic Resonance Imaging of the Hand versus Anticyclic Citrullinated Peptide Antibody Testing to Confirm the Diagnosis of Clinically Suspected Early Rheumatoid Arthritis in the Absence of Rheumatoid Factor and Radiographic Erosions. Semin Arthritis Rheum, 2008, 24.
134. Yamane T, Hashiramoto A, Tanaka Y, et al. Easy and Accurate Diagnosis of Rheumatoid Arthritis Using Anti-Cyclic Citrullinated Peptide 2 Antibody, Swollen Joint Count, and C-Reactive Protein/ Rheumatoid Factor. J Rheumatol, 2008, 35(3): 414-420.
135. Alexiou I, Germenis A, Ziogas A, et al. Diagnostic value of anti-cyclic citrullinated peptide antibodies in Greek patients with rheumatoid arthritis. BMC Musculoskelet Disord, 2007,20(8):37.
136. Ate A, Karaaslan Y, Aksaray S. Predictive value of antibodies to cyclic citrullinated peptide in patients with early arthritis. Clin Rheumatol, 2007, 26(4): 499-504.
137. Inanc N, Dalkilic E, Kamali S, et al. Anti-CCP antibodies in rheumatoid arthritis and psoriatic arthritis. Clin Rheumatol, 2007, 26(1): 17-23.
138. Koca SS, Akbulut H, Dag S, et al. Anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis and Behçet’s disease. Tohoku J Exp Med, 2007, 213(4): 297-304.
139. Kudo-Tanaka E, Ohshima S, Ishii M, et al. Autoantibodies to cyclic citrullinated peptide 2 (CCP2) are superior to other potential diagnostic biomarkers for predicting rheumatoid arthritis in early undifferentiated arthritis. Clin Rheumatol, 2007, 26(10): 1627-33.
140. Luis Caro-Oleas J, Fernández-Suárez A, Reneses Cesteros S, et al. Diagnostic usefulness of a third-generation anti-cyclic citrulline antibody test in patients with recent-onset polyarthritis. Clin Chem Lab Med, 2007, 45(10): 1396 - 1401.
141. Lutteri L, Malaise M, Chapelle JP. Comparison of second- and thirdgeneration anti-cyclic citrullinated peptide antibodiesassays for detecting rheumatoid arthritis. Clin Chim Acta, 2007, 386(1-2): 76-81.
142. Sghiri R, Bouagina E, Zaglaoui H, et al. Diagnostic performances of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis. Rheumatol Int, 2007,27(12):1125-30.
143. Silveira IG, Burlingame RW, von Mühlen CA, et al. Anti-CCP antibodies have more diagnostic impact than rheumatoid factor (RF) in a population tested for RF. Clin Rheumatol, 2007, 26(11): 1883-1889.
144. Soós L, Szekanecz Z, Szabó Z, et al. Clinical evaluation of antimutated citrullinated vimentin by ELISA in rheumatoid arthritis. J Rheumatol, 2007, 34(8): 1658-1663.
145. Wu R, Shovman O, Zhang Y, et al. Increased prevalence of antithird generation cyclic citrullinated peptide antibodies in patients with rheumatoid arthritis and CREST syndrome. Clin Rev Allergy Immunol, 2007, 32(1): 47-56.
146. Ceccato F, Roverano S, Barrionuevo A, et al. The role of anticyclic citrullinated peptide antibodies in the differential diagnosis of elderly-onset rheumatoid arthritis and Polymyalgia rheumatica. Clin Rheumatol, 2006, 25(6): 854-857.
147. Dejaco C, Klotz W, Larcher H, et al. Diagnostic value of antibodies against a modified citrullinated vimentin in rheumatoid arthritis. Arthritis Res Ther, 2006, 8(4): 119.
148. Hill JA, Al-Bishri J, Gladman DD, et al. Serum autoantibodies that bind citrullinated fibrinogen are frequently found in patients with rheumatoid arthritis. J Rheumatol, 2006, 33(11): 2115-2119.
149. Korkmaz C, Us T, Kaifolu T, et al. Anti-cyclic citrullinated peptide (CCP) antibodies in patients with long-standing rheumatoid arthritis and their relationship with extra-articular manifestations. Clin Biochem, 2006, 39(10): 961-965.
150. López-Longo FJ, Rodríguez-Mahou M, Sánchez-Ramón S, et al. Anti-cyclic citrullinated peptide versus anti-Sa antibodies in diagnosis of rheumatoid arthritis in an outpatient clinic for connective tissue disease and spondyloarthritis. J Rheumatol, 2006, 33(8): 1476-1481.
151. Matsui T, Shimada K, Ozawa N, et al. Diagnostic utility of anti-cyclic citrullinated peptide antibodies for very early rheumatoid arthritis. J Rheumatol, 2006, 33(12): 2390-2397.
152. Mikuls TR, Holers VM, Parrish L, et al. Anti-cyclic citrullinated peptide antibody and rheumatoid factor isotypes in African Americans with early rheumatoid arthritis. Arthritis Rheum, 2006, 54(9): 3057-3059.
153. Panchagnula R, Rajiv SR, Prakash J, et al. Role of anticyclic citrullinated peptide in the diagnosis of early rheumatoid factornegative suspected rheumatoid arthritis: is it worthwhile to order the test? J Clin Rheumatol, 2006, 12(4): 172-175.
154. Quinn MA, Gough AK, Green MJ, et al. Anti-CCP antibodies measured at disease onset help identify seronegative rheumatoid arthritis and predict radiological and functional outcome. Rheumatology (Oxford), 2006, 45(4): 478-480.
155. Russell AS, Devani A, Maksymowych WP. The role of anti-cyclic citrullinated peptide antibodies in predicting progression of palindromic rheumatism to rheumatoid arthritis. J Rheumatol, 2006, 33(7): 1240 - 1242.
156. Spadaro A, Riccieri V, Alessandri C, et al. [Usefulness of anti-cyclic citrullinate peptide antibodydetermination in synovial fluid analysis of patients with rheumatoid arthritis]. Reumatismo, 2006, 58(2): 116-120.
157. van Venrooij WJ, Zendman AJW, Pruijn GJM. Autoantibodies to citrullinated antigens in (early) rheumatoid arthritis. Autoimmune, 2006, 6(1): 37-41.
158. Abreu I, Laroche P, Bastos A, et al. Multiplexed immunoassay for detection of rheumatoid factors by FIDIS™ technology Ann. New York Acad Sci, 2005, 1050: 357 - 363.
159. Aotsuka S, Okawa-Takatsuji M, Nagatani K, et al. A retrospective study of the fluctuation in serum levels of anti-cyclic citrullinated peptide antibody in patients with rheumatoid arthritis. Clin Exp Rheumatol, 2005, 23(4): 475-481.
160. Choi SW, Lim MK, Shin DH, et al. Diagnostic performances of anticyclic citrullinated peptides antibody and antifilaggrin antibody in Korean patients with rheumatoid arthritis. J Korean Med Sci, 2005, 20(3): 473-478.
161. Fernández-Suárez A, Reneses S, Wichmann I, et al. Efficacy of three ELISA measurements of anti-cyclic citrullinated peptide antibodies in the early diagnosis of rheumatoid arthritis. Clin Chem Lab Med, 2005, 43(11): 1234-1239.
162. García-Berrocal B, González C, Pérez M, et al. Anti-cyclic citrullinated peptide autoantibodies in IgM rheumatoid factorpositive patients. Clin Chim Acta, 2005, 354(1-2): 123-130.
163. Greiner A, Plischke H, Kellner H, et al. Association of anti-cyclic citrullinated peptide antibodies, anti-citrullin antibodies, and IgM and IgA rheumatoid factors with serological parameters of disease activity in rheumatoid arthritis. Ann N Y Acad Sci, 2005, 1050: 295-303.
164. Kamali S, Polat NG, Kasapoglu E, et al. Anti-CCP and antikeratin antibodies in rheumatoid arthritis, primary Sjögren’s syndrome, and Wegener’s granulomatosis. Clin Rheumatol, 2005, 24(6): 673-676.
165. Korendowych E, Owen P, Ravindran J, et al. The clinical and genetic associations of anti-cyclic citrullinated peptide antibodies in psoriatic arthritis. Rheumatology, 2005, 44(8): 1056-1060.
166. Kwok JS, Hui KH, Lee TL, et al. Anti-cyclic citrullinated peptide: diagnostic and prognostic values in juvenile idiopathic arthritis and rheumatoid arthritis in a Chinese population. Scand J Rheumatol, 2005, 34(5): 359-366.
167. Nell VP, Machold KP, Stamm TA, et al. Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis. Ann Rheum Dis, 2005, 64(12): 1731-1736.
168. Nielen MM, van der Horst AR, van Schaardenburg D, et al. Antibodies to citrullinated human fibrinogen (ACF) have diagnostic and prognostic value in early arthritis. Ann Rheum Dis, 2005, 64(8): 1199-1204.
169. Raza K, Breese M, Nightingale P, et al. Predictive value of antibodies to cyclic citrullinated peptide in patients with very early inflammatory arthritis. J Rheumatol, 2005, 32(2): 231-238.
170. Sauerland U, Becker H, Seidel M, et al. Clinical utility of the anti-CCP assay: experiences with 699 patients. Ann N Y Acad Sci, 2005, 1050: 314-318.
171. Tampoia M, Brescia V, Fontana A, et al. Anti-cyclic citrullinated peptide autoantibodies measured by an automated enzyme immunoassay: analytical performance and clinical correlations. Clin Chim Acta, 2005, 355(1-2): 137-144.
172. van Gaalen FA, Visser H, Huizinga TW. A comparison of the diagnostic accuracy and prognostic value of the first and second anticyclic citrullinated peptides (CCP1 and CCP1) autoantibody tests for rheumatoid arthritis. Ann Rheum Dis, 2005, 64(10): 1510-1512.
173. Berglin E, Padyukov L, Sundin U, et al. A combination of autoantibodies to cyclic citrullinated peptide (CCP) and HLA-DRB0 locus antigens is strongly associated with future onset of rheumatoid arthritis. Arthritis Res Ther, 2004, 6(4): 303-308.
174. Bombardieri M, Alessandri C, Labbadia G, et al. Valesini G Role of anti-cyclic citrullinated peptide antibodies in discriminating patients with rheumatoid arthritis from patients with chronic hepatitis C infection-associated polyarticular involvement. Arthritis Res Ther, 2004, 6(2): 137-141.
175. Bongi SM, Manetti R, Melchiorre D, et al. Anti-cyclic citrullinated peptide antibodies are highly associated with severe bone lesions in rheumatoid arthritis anti-CCP and bone damage in RA. Autoimmunity, 2004, 37(6-7): 495-501.
176. Correa PA, Tobón GJ, Citera G, et al. [Anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis: relation with clinical features, cytokines and HLA-DRB0]. Biomedica, 2004, 24(2): 140-152.
177. De Rycke L, Peene I, Hoffman IE, et al. Rheumatoid factor and anticitrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate, and extraarticular manifestations. Ann Rheum Dis, 2004, 63(12): 1587-1593.
178. Dubucquoi S, Solau-Gervais E, Lefranc D, et al. Evaluation of anticitrullinated filaggrin antibodies as hallmarks for the diagnosis of rheumatic diseases. Ann Rheum Dis, 2004, 63(4): 415-419.
179. Girelli F, Foschi FG, Bedeschi E, et al. Is Anti Cyclic citrullinated peptide a useful laboratory test for the diagnosis of rheumatoid arthritis? Eur Ann Allergy Clin Immunol, 2004, 36(4): 127-130.
180. Grootenboer-Mignot S, Nicaise-Roland P, Delaunay C, et al. Second generation anti-cyclic citrullinated peptide (anti-CCP1) antibodies can replace other anti-filaggrin antibodies and improve rheumatoid arthritis diagnosis. Scand J Rheumatol, 2004, 33(4): 218-220.
181. Hitchon CA, Alex P, Erdile LB, et al. A distinct multicytokine profile is associated with anti-cyclical citrullinated peptide antibodies in patients with early untreated inflammatory arthritis. J Rheumatol, 2004, 31(12): 2336-2346.
182. Jansen TL, Bruyn GA. Diagnostic value of antcyclic citrullinated peptide antibody in rheumatoid arthritis. J Rheumatol, 2004, 31(5): 1012-1013.
183. Lopez-Hoyos M, Ruiz de Alegria C, Blanco R, et al. Clinical utility of anti-CCP antibodies in the differential diagnosis of elderly-onset rheumatoid arthritis and Polymyalgia rheumatica. Rheumatology (Oxford), 2004, 43(5): 655-657.
184. Söderlin MK, Kastbom A, Kautiainen H, et al. Antibodies against cyclic citrullinated peptide (CCP) and levels of cartilage oligomeric matrix protein (COMP) in very early arthritis: relation to diagnosis and disease activity. Scand J Rheumatol, 2004, 33(3): 185-188.
185. Vallbracht I, Rieber J, Oppermann M, et al. Diagnostic and clinical value of anti-cyclic citrullinated peptide antibodies compared with rheumatoid factor isotypes in rheumatoid arthritis. Ann Rheum Dis, 2004, 63(9): 1079-1084.
186. van Venrooij WJ, Vossenaar ER, Zendman AJ Anti-CCP antibodies: the new rheumatoid factor in the serology ofrheumatoid arthritis. Autoimmun Rev, 2004, 3(1): 17-19.
187. Vittecoq O, Incaurgarat B, Jouen-Beades F, et al. Autoantibodies recognizing citrullinated rat filaggrin in an ELISA using citrullinated and non-citrullinated recombinant proteins as antigens are highly diagnostic for rheumatoid arthritis. Clin Exp Immunol, 2004, 135(1): 173-180.
188. Bas S, Genevay S, Meyer O, et al. Anti-cyclic citrullinated peptide antibodies, IgM and IgA rheumatoid factors in the diagnosis and prognosis of rheumatoid arthritis. Rheumatology (Oxford), 2003, 42(5): 677-680.
189. Jansen LM, van Schaardenburg D, van der Horst-Bruinsma I, et al. The predictive value of anti-cyclic citrullinated peptide antibodies in early arthritis. J Rheumatol, 2003, 30(8): 1691-1695.
190. Lee DM, Schur PH. Clinical utility of the anti-CCP assay in patients with rheumatic diseases. Ann Rheum Dis, 2003, 62(9): 870-874.
191. Rantapää-Dahlqvist S, de Jong BA, Berglin E, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum, 2003, 48(10): 2741-2749.
192. Saraux A, Berthelot JM, Devauchelle V, et al. Value of antibodies to citrulline-containing peptides for diagnosing early rheumatoid arthritis. J Rheumatol, 2003, 30(12): 2535-2539.
193. Suzuki K, Sawada T, Murakami A, et al. High diagnostic performance of ELISA detection of antibodies to citrullinated antigens in rheumatoid arthritis. Scand J Rheumatol, 2003, 32(4): 197-204.
194. Zeng X, Ai M, Tian X, et al. Diagnostic value of anti-cyclic citrullinated Peptide antibody in patients with rheumatoid arthritis. J Rheumatol, 2003, 30(7): 1451-1455.
195. Bas S, Perneger TV, Seitz M, et al. Diagnostic tests for rheumatoid arthritis: comparison of anti-cyclic citrullinated peptide antibodies, anti-keratin antibodies and IgM rheumatoid factors. Rheumatology (Oxford), 2002, 41(7): 809-814.
196. Jansen AL, van der Horst-Bruinsma I, van Schaardenburg D, et al. Rheumatoid factor and antibodies to cyclic citrullinated Peptide differentiate rheumatoid arthritis from undifferentiated polyarthritis in patients with early arthritis. J Rheumatol, 2002, 29(10): 2074-2076.
197. Vincent C, Nogueira L, Sebbag M, et al. Detection of antibodies to deiminated recombinant rat filaggrin by enzyme-linked immunosorbent assay: a highly effective test for the diagnosis of rheumatoid arthritis. Arthritis Rheum, 2002, 46(8): 2051-2058.
198. Bizzaro N, Mazzanti G, Tonutti E, et al. Diagnostic accuracy of the anti-citrulline antibody assay for rheumatoid arthritis. Clin Chem, 2001, 47(6): 1089-1093.
199. Goldbach-Mansky R, Lee J, McCoy A, et al. Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset. Arthritis Res, 2000, 2(3): 236-243.
200. Schellekens GA, Visser H, de Jong BA, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum, 2000, 43(1): 155-163.

Previous Article
《中国呼吸与危重监护杂志》稿约
Next Article
《中国呼吸与危重监护杂志》稿约

Chinese Journal of Evidence-Based Medicine

Quality Assessment of Diagnostic Studies on Using Anti-cyclic Citrullonated Peptide Antibody to Diagnose Rheumatoid Arthritis

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content